Rasagiline added to dopamine agonist has small benefit in Parkinson’s

From Clinical Neurology News, 25 June 2013:

Rasagiline is safe and efficacious as add-on therapy in patients with early Parkinson’s disease whose symptoms are not adequately controlled with dopamine agonist monotherapy, results from a randomized, double-blind placebo-controlled study suggest.

Data from the ANDANTE study showed that adding rasagiline (1 mg/day) to dopamine agonist therapy led to an additional mean 2.4-point reduction (P = .012; 95% CI, –4.3 to –0.5) in the Unified Parkinson’s Disease Rating Scale (UPDRS) total score at 18 weeks, compared with placebo.

The 18-week phase IV study involved 328 patients with Parkinson’s disease whose symptoms were poorly controlled with dopamine agonist monotherapy.

Researchers also observed an additional mean 1.8-point improvement (P =.007; 95% CI, –3.1 to –0.5) in the UPDRS motor scores and a nonsignificant improvement in the activities of daily living (ADL) score, compared with placebo.

Lead author Dr. Robert Hauser, director of the University of South Florida’s Parkinson’s disease and movement disorder center in Tampa, said rasagiline – a selective, irreversible inhibitor of monoamine oxidase type B – is currently approved in the United States under the brand name Azilect as an adjunct to levodopa in patients with motor fluctuations, and as monotherapy earlier in the disease.

However, this study examined its use in patients whose symptoms were not being controlled by dopamine agonists but who had not yet started on levodopa.

“That was the question: ‘If patients are on a dopamine agonist and the disease is progressing and patients aren’t doing as well as you would like, is adding rasagiline an option? Is it helpful?’ ” Dr. Hauser said in an interview at the international congress of Parkinson’s Disease and Movement Disorders. Read more.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s